Literature DB >> 9269548

The natural history and management of Merkel cell carcinoma of the skin: a review of 22 patients treated at the Royal Marsden Hospital.

P Savage1, D Constenla, C Fisher, J M Thomas, M E Gore.   

Abstract

Merkel cell carcinoma is a rare skin malignancy, which primarily affects the elderly. Currently, there is only limited data on the natural history of this condition and no consensus on its optimum management. We have reviewed the natural history and management of 22 patients with Merkel cell carcinoma, who were treated at the Royal Marsden Hospital between 1985 and 1994. The median age at diagnosis was 75 years (range 55-96), with the head and neck region being the most common site of disease (nine patients: 41%). Seventeen patients (77%) presented with skin disease, three (14%) with regional lymphadenopathy and two (9%) with metastatic disease. Of the Stage I patients, 41% developed local recurrence postoperatively at a median time to relapse of 12 months. Those with head and neck disease had the highest risk of local recurrence, which occurred in 62.5% of this group. Stage I patients also had a high risk of disease progression, with 53% developing regional lymphadenopathy or visceral metastases. The median survival for all disease stages was 47 months. The treatment of unresectable primary or recurrent disease with radiotherapy led to valuable long term control in four of nine patients treated. Six courses of chemotherapy were administered; one brief complete response was observed, occurring in a patient treated with cyclophosphamide, vincristine and doxorubicin. The data in this study confirms the predilection for the elderly and the aggressive nature of Merkel cell carcinoma, with only four of 17 Stage I patients remaining disease free. To clarify the role of adjuvant postoperative radiotherapy and to establish the appropriate use of chemotherapy in metastatic spread of this rare malignancy will require further studies with multicentre cooperation.

Entities:  

Mesh:

Year:  1997        PMID: 9269548     DOI: 10.1016/s0936-6555(97)80073-8

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  8 in total

1.  A Case of Merkel Cell Carcinoma: Treated with Wide Excision and Adjuvant Radiotherapy.

Authors:  Hyun Ju Lee; Gyeong Hun Park; Sung Eun Chang; Mi Woo Lee; Jee Ho Choi; Kee Chan Moon
Journal:  Ann Dermatol       Date:  2008-06-30       Impact factor: 1.444

2.  Multimodality management for 145 cases of Merkel cell carcinoma.

Authors:  Patricia Tai; Edward Yu; Avi Assouline; Ji Dong Lian; Kurian Joseph; Thomas Miale; Claude Krzisch
Journal:  Med Oncol       Date:  2009-12-01       Impact factor: 3.064

3.  Merkel cell carcinoma with lymph node metastasis in the absence of a primary site: Case report and literature review.

Authors:  Min Zhao; Mao-Bin Meng
Journal:  Oncol Lett       Date:  2012-09-19       Impact factor: 2.967

4.  Merkel cell carcinoma: a retrospective study on 48 cases and review of literature.

Authors:  Fernando Cirillo; Marco Vismarra; Ines Cafaro; Mario Martinotti
Journal:  J Oncol       Date:  2012-09-13       Impact factor: 4.375

5.  A practical update of surgical management of merkel cell carcinoma of the skin.

Authors:  Patricia Tai
Journal:  ISRN Surg       Date:  2013-01-30

Review 6.  Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma.

Authors:  Paul Nghiem; Howard L Kaufman; Murtuza Bharmal; Lisa Mahnke; Hemant Phatak; Jürgen C Becker
Journal:  Future Oncol       Date:  2017-03-28       Impact factor: 3.404

7.  Merkel cell carcinoma.

Authors:  Virve Koljonen
Journal:  World J Surg Oncol       Date:  2006-02-08       Impact factor: 2.754

8.  Neuroendocrine carcinoma arising in soft tissue: three case reports and literature review.

Authors:  Steve L Hyer; Jonathan McAleese; Clive L Harmer
Journal:  World J Surg Oncol       Date:  2007-07-09       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.